Skinsense Medical Research

Running trials

• Not yet recruiting

  A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis

  NCT07914231· Phase 2· Source

• Active, not recruiting

  A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

  NCT07265479· Phase 3· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

  NCT06832618· Phase 3· Source

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

  NCT06516965· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

  NCT06095102· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Psoriasis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Source

• Completed

  A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

  NCT06588738· Phase 3· Source

• Completed

  A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

  NCT06224192· Phase 3· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Source

• Completed

  A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

  NCT05398445· Phase 3· Source